



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Dt: 17 October 2023

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Stock Code: NSE: SHILPAMED/BSE-530549

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

**Shilpa Medicare Ltd, Unit IV, Jadcherla, Telangana has cleared
TGA, Australia GMP inspection**

This is to inform you that the Company's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana state has successfully closed-out a GMP Inspection from TGA, Australia as per communication received on 17 th October 2023.

The facility is involved in manufacturing, packaging, labelling, testing and release of finished dosage forms (sterile injections and non-sterile oral solids) for the treatment of various forms of cancer and adjuvant therapy.

This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years.

The successful closure of this inspection will allow the company to register and market its products in Australia and other rest of world markets which recognize Australian GMP.

The company remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.

With regards,

For Shilpa Medicare Ltd.

Ritu Tiwary
Company Secretary